552 related articles for article (PubMed ID: 32414364)
1. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
[TBL] [Abstract][Full Text] [Related]
2. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.
Barış VÖ; Dinçsoy AB; Gedikli E; Zırh S; Müftüoğlu S; Erdem A
Cardiovasc Toxicol; 2021 Sep; 21(9):747-758. PubMed ID: 34089496
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ
J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996
[TBL] [Abstract][Full Text] [Related]
6. Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat.
Younis F; Leor J; Abassi Z; Landa N; Rath L; Hollander K; Naftali-Shani N; Rosenthal T
J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):358-371. PubMed ID: 29627992
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin directly improves diastolic function in human heart failure.
Pabel S; Wagner S; Bollenberg H; Bengel P; Kovács Á; Schach C; Tirilomis P; Mustroph J; Renner A; Gummert J; Fischer T; Van Linthout S; Tschöpe C; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Hamdani N; Sossalla S
Eur J Heart Fail; 2018 Dec; 20(12):1690-1700. PubMed ID: 30328645
[TBL] [Abstract][Full Text] [Related]
8. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
[TBL] [Abstract][Full Text] [Related]
11. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
[TBL] [Abstract][Full Text] [Related]
12. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.
Gyöngyösi M; Lukovic D; Zlabinger K; Spannbauer A; Gugerell A; Pavo N; Traxler D; Pils D; Maurer G; Jakab A; Riesenhuber M; Pircher A; Winkler J; Bergler-Klein J
Cardiovasc Res; 2020 Apr; 116(5):970-982. PubMed ID: 31346605
[TBL] [Abstract][Full Text] [Related]
13. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
14. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity.
Milano G; Biemmi V; Lazzarini E; Balbi C; Ciullo A; Bolis S; Ameri P; Di Silvestre D; Mauri P; Barile L; Vassalli G
Cardiovasc Res; 2020 Feb; 116(2):383-392. PubMed ID: 31098627
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
Shi L; Zhu D; Wang S; Jiang A; Li F
Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
Connelly KA; Zhang Y; Desjardins JF; Thai K; Gilbert RE
Cardiovasc Diabetol; 2018 Jul; 17(1):99. PubMed ID: 29981571
[TBL] [Abstract][Full Text] [Related]
17. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Krasnova M; Kulikov A; Okovityi S; Ivkin D; Karpov A; Kaschina E; Smirnov A
Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1649-1658. PubMed ID: 32377771
[TBL] [Abstract][Full Text] [Related]
19. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
[TBL] [Abstract][Full Text] [Related]
20. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Barron B; Mayoux E; Rector RS; Whaley-Connell A; DeMarco VG
Cardiovasc Diabetol; 2017 Jan; 16(1):9. PubMed ID: 28086951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
